Rationalization of therapy of upper gastrointestinal tract diseases (not only) in geriatrics
Authors:
Kroupa Radek; Skutil Tomáš; Dolina Jiří
Authors‘ workplace:
Interní gastroenterologická klinika Lékařské fakulty Masarykovy univerzity a Fakultní nemocnice Brno
Published in:
Geriatrie a Gerontologie 2024, 13, č. 3: 144-149
Category:
Review Article
Overview
The management of diseases of the upper gastrointestinal tract is based on anamnestic data mainly. In selected cases, specialized gastroenterological examination and endoscopy are indicated. Therapy of upper gastrointestinal tract disorders is usually based on treatment inhibiting gastric acid production. Its initiation and duration of administration are based on the nature of the disease and follow-up of the patient’s condition. In a significant proportion of particularly geriatric patients, the indication for administration of proton pump inhibitors is unclear and their use is unnecessary, with a theoretical increase in the risk of adverse effects. The approach to patients with upper gastrointestinal tract diseases and pathways to rational prescription and ways of de-prescribing of non-indicated therapy are discussed in a review article.
Keywords:
proton pump inhibitors, gastroesophageal reflux disease, dyspepsia, upper gastrointestinal bleeding, prevention, adverse effect, de-prescribing
Sources
1. Špičák J. Inhibitory protonové pumpy – komplikace, interakce, farmakogenetika. Gastroenterologie a hepatologie 2014; 57–58.
2. Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology 2017; 152(4): 706–715.
3. Black CJ, Paine PA, Agrawal A, et al. British Society of Gastroenterology guidelines on the management of functional dyspepsia. Gut 2022; 71: 1697–1723.
4. Kroupa R, Dolina J. Rizika dlouhodobé antisekreční terapie. Vnitř Lék 2010; 56: 115–119.
5. Kroupa R, Cyrany J, Dolina J, et al. Doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře. Gastroenterologie. Příznaky a onemocnění horní části trávicího traktu. Praha 2024.
6. Abrignani MG, Gatta L, Gabrielli D, et al. Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). Eur J Intern Med 2021; 85: 1–13.
7. Venerito M, Schneider C, Costanzo R, et al. Contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients on nonsteroidal anti-inflammatory drugs, antiplatelet agents, anticoagulants, corticosteroids and selective serotonin reuptake inhibitors. Aliment Pharmacol Ther 2018; 47(11): 1464–1471.
8. Ahn N, Nolde M, Krause E, et al. Do proton pump inhibitors in-
crease the risk of dementia? A systematic review, meta-analysis and bias analysis. Br J Clin Pharmacol 2023; 89(2): 602–616.
9. Kroupa R, Katinova I, Pavlik T, et al. Incidence trends of esophageal cancer in the Czech Republic by histological subtype and stage and prescription rate of acid suppressing drugs. Cancer Epidemiol 2020; 69: 101853.
10. Cao F, Chen CX, Wang M, et al. Updated meta-analysis of controlled observational studies: Proton-pump inhibitors and risk of Clostridium difficile infection. J Hosp Infect 2018; 98(1): 4–13.
11. Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG Clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2022; 117(1): 27–56.
12. Targownik LE, Fisher DA, Saini SD. AGA Clinical practice update on de-prescribing of proton pump inhibitors: expert review. Gastroenterology 2022; 162(4): 1334–1342.
13. Hojo M, Asaoka D, Shimada Y, et al. Strategies for discontinuation of proton pump inhibitors (PPIs) in patients with long-term PPI administration: a randomized controlled trial. BMC Gastroenterol 2022; 22(1): 21.
14. Dixon R, Bolt J. Appropriateness of proton pump inhibitor therapy in an ambulatory geriatrics clinic: A retrospective cross-sectional analysis. Can Pharm J (Ott) 2023; 156(6): 331–
336.
15. Aubert CE, Blum MR, Gastens V, et al. Prescribing, deprescribing and potential adverse effects of proton pump inhibitors in older patients with multimorbidity: an observational study. CMAJ Open 2023; 11: E170–E178.
16. Leszcynski L, Bente J. Develop-
ment and implementation of a pharmacist-led proton pump inhibitor deprescribing algorithm in a geriatric ambulatory office. Sr Care Pharm 2023; 38(3): 105–112.
Labels
Geriatrics General practitioner for adults Orthopaedic prostheticsArticle was published in
Geriatrics and Gerontology
2024 Issue 3
Most read in this issue
- Population ageing in the Czech Republic: challenges for the health and social system
- Swallowing disorders in old age
- Muscle dynamopenia and sarcopenia in old age
- Frailty assessment in renal transplant candidates using comprehensive geriatric assessment